secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-02-01T23:59:59+00:00
Accession:  0001140361-23-003906
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant reports preliminary Q3 cash ~$1.5B; VTAMA revenue guided $9.0-9.5M
--------------------------------------------------------------------------

- Cash, cash equivalents and restricted cash ~$1.5B at Dec 31, 2022; pro-forma $1.7B after expected $115M Myovant proceeds.
- Net product revenues from VTAMA expected $9.0M to $9.5M for Q3 ending Dec 31, 2022.
- Myovant transaction with Sumitomo Pharma expected to close by March 31, 2023.
- Preliminary unaudited results; final Q3 2022 financials to be reported in subsequent SEC filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123003906/0001140361-23-003906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123003906/ny20006513x3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-003906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer